Greenleaf Trust Cuts Holdings in Stryker Co. (NYSE:SYK)

Greenleaf Trust reduced its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,488,307 shares of the medical technology company's stock after selling 840,331 shares during the quarter. Stryker comprises about 59.4% of Greenleaf Trust's investment portfolio, making the stock its largest holding. Greenleaf Trust owned 4.87% of Stryker worth $5,536,508,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Beaumont Financial Advisors LLC raised its stake in shares of Stryker by 2.7% during the fourth quarter. Beaumont Financial Advisors LLC now owns 2,150 shares of the medical technology company's stock valued at $644,000 after purchasing an additional 57 shares in the last quarter. Knights of Columbus Asset Advisors LLC grew its holdings in Stryker by 1.8% during the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 18,038 shares of the medical technology company's stock worth $5,402,000 after acquiring an additional 312 shares during the period. Colton Groome Financial Advisors LLC grew its holdings in Stryker by 10.6% during the fourth quarter. Colton Groome Financial Advisors LLC now owns 826 shares of the medical technology company's stock worth $247,000 after acquiring an additional 79 shares during the period. Fidelis Capital Partners LLC grew its holdings in Stryker by 49.6% during the fourth quarter. Fidelis Capital Partners LLC now owns 1,939 shares of the medical technology company's stock worth $581,000 after acquiring an additional 643 shares during the period. Finally, Western Wealth Management LLC grew its holdings in Stryker by 5.5% during the fourth quarter. Western Wealth Management LLC now owns 1,467 shares of the medical technology company's stock worth $439,000 after acquiring an additional 77 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company's stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 in the last three months. 5.90% of the stock is owned by insiders.

Stryker Stock Down 0.6 %

NYSE SYK traded down $2.02 during trading on Friday, reaching $325.43. 1,784,380 shares of the company's stock were exchanged, compared to its average volume of 1,271,581. Stryker Co. has a fifty-two week low of $249.98 and a fifty-two week high of $361.41. The firm has a market capitalization of $123.82 billion, a PE ratio of 39.54, a P/E/G ratio of 2.71 and a beta of 0.89. The company has a current ratio of 1.58, a quick ratio of 0.97 and a debt-to-equity ratio of 0.59. The company's fifty day simple moving average is $350.34 and its 200-day simple moving average is $312.14.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping analysts' consensus estimates of $3.27 by $0.19. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same period last year, the company posted $3.00 EPS. The business's quarterly revenue was up 11.8% compared to the same quarter last year. Sell-side analysts predict that Stryker Co. will post 11.86 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. Stryker's dividend payout ratio is 38.79%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SYK shares. Wells Fargo & Company lifted their target price on Stryker from $336.00 to $364.00 and gave the stock an "overweight" rating in a report on Wednesday, January 31st. TD Cowen lifted their target price on Stryker from $365.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, April 11th. StockNews.com raised Stryker from a "hold" rating to a "buy" rating in a report on Tuesday, January 23rd. Royal Bank of Canada lifted their target price on Stryker from $360.00 to $386.00 and gave the stock an "outperform" rating in a report on Monday. Finally, Truist Financial lifted their price target on Stryker from $330.00 to $345.00 and gave the stock a "hold" rating in a research note on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $340.45.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.